Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy

Journal of Asthma and Allergy

Volumn 9, Issue , 2016, Pages 65-70

  Horiuchi, Kazuya ^a   Kasahara, Keita ^a   Kuroda, Yusuke ^a   Morohoshi, Haruna ^a   Hagiwara, Yosuke ^a   Ishii, Gen ^a  

^a SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Asthma; Fluticasone propionate; Long Term outcome; Salmeterol; Step down

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; EVALUATION AND FOLLOW UP; EXPIRATORY FLOW RATE; FEMALE; FORCED EXPIRATORY FLOW; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 84961620139     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S93782     Document Type: Article

References (15)

1. Greening AP, Ind PW, Northfield M. Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen and Hanburys Limited UK Study Group. Lancet. 1994;344(8917):219-224.
2. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbation of asthma: formoterol and corticosteroids establishing therapy (FACET) International Study Group. N Eng J Med. 1997;337(20):1405-1411.
3. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists the influence of values. N Engl J Med. 2009;360(16): 1592-1595.
4. Nelson HS, Weiss ST, Bleecker ER, et al; SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
5. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. NEngl J Med. 2010;362(13): 1169-1171.
6. Thomas M, Kay S, Pike J, et al. The asthma control test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim CareRespir J. 2009;18(1):41-49.
7. Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar PK, Chung KF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. Eur Respir J. 2014;43(2):474-484.
8. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres JL, Attali V. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double blind randomised study. Respir Med. 2008;102(8):1124-1131.
9. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting P2-agonist step-off in patients with controlled asthma. Arch Intern Med. 2012;172(18):1365-1375.
10. Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-Comstock J, Williams LK. The relationship between combination inhaled corticosteroid and long-acting P-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol. 2012;129(5):1274-1279.
11. Pedersen S, O'Byrne PM. Combination inhaled corticosteroid and long-acting P2-agonist use and severe asthma exacerbations. J Allegy Clin Immunol. 2012;129(5):1280-1281.
12. Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. 2010;123(4):322-328.
13. Adachi M, Aizawa H, Ishihara K, et al. Comparison of salmeterol/ fluticasone propionate (FP) combination with FP + sustained release theophylline in moderate asthma patients. Respir Med. 2008;102(7):1055-1064.
14. Ketai L, Harkins M, Fiato KL, Iwamoto GK. Exhaled nitric oxide and bronchial wall thickening in asthmatics during and after acute exacerbation: evidence of bronchial wall remodeling. J Asthma. 2005;42(8):667-671.
15. Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Eng J Med. 2011;364(21):2006-2015.